WO2010115175A1 - Control of copolymer compositions - Google Patents

Control of copolymer compositions Download PDF

Info

Publication number
WO2010115175A1
WO2010115175A1 PCT/US2010/029896 US2010029896W WO2010115175A1 WO 2010115175 A1 WO2010115175 A1 WO 2010115175A1 US 2010029896 W US2010029896 W US 2010029896W WO 2010115175 A1 WO2010115175 A1 WO 2010115175A1
Authority
WO
WIPO (PCT)
Prior art keywords
protected
glatiramer acetate
copolymer
depolymerization
treating
Prior art date
Application number
PCT/US2010/029896
Other languages
French (fr)
Inventor
Claire Coleman
John Schaeck
Alicia Thompson
Original Assignee
Momenta Pharmaceticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42230467&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2010115175(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Momenta Pharmaceticals, Inc. filed Critical Momenta Pharmaceticals, Inc.
Priority to ES10715379T priority Critical patent/ES2523732T5/en
Priority to RU2011144566/05A priority patent/RU2011144566A/en
Priority to EP10715379.3A priority patent/EP2414384B2/en
Publication of WO2010115175A1 publication Critical patent/WO2010115175A1/en
Priority to IL215072A priority patent/IL215072A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis

Definitions

  • Glatiramer acetate also known as copolymer- 1 and marketed as the active ingredient in COPAXONE® by Teva Pharmaceutical Industries Ltd., Israel
  • glatiramer acetate consists of the acetate salts of synthetic polypeptides containing four naturally occurring amino acids: L- glutamic acid, L-alanine, L- tyrosine, and L-lysine with a reported average molar fraction of 0.141, 0.427, 0.095, and 0.338, respectively.
  • glatiramer acetate is designated L-glutamic acid polymer with L- alanine, L-lysine and L- tyrosine, acetate (salt). Its structural formula is:
  • the invention is based, at least in part, on the identification of methods for controlling the level of L-pyroGlutamic Acid (pyro-Glu) in glatiramer acetate (GA).
  • Pyro-Glu is present in GA, and the ability to control the level of pyro-Glu in GA is useful in controlling both product and process quality in the manufacture of GA.
  • Described herein is a method for preparing a composition comprising glatiramer acetate, comprising: polymerizing N-carboxy anhydrides of L-alanine, benzyl-protected L- glutamic acid, trifluoroacetic acid (TFA) protected L-lysine and L-tyrosine to generate a protected copolymer (Intermediate- 1); treating the protected copolymer to partially depolymerize the protected copolymer and deprotect benzyl protected groups thereby generating a partially depolymerized, benzyl -deprotect ed product (Intermediate-2); treating the partially depolymerized product to deprotect TFA-protected lysines thereby generating a TFA- deprotected product (Intermediate-3) and further processing the Intermediate-3 to create glatiramer acetate, wherein the improvement comprises: having water present during at least a portion of the depolymerization step.
  • a method for preparing a composition comprising glatiramer acetate comprising: polymerizing N-carboxy anhydrides of L-alanine, benzyl- protected L-glutamic acid, trifluoroacetic acid (TFA) protected L-lysine and L-tyrosine to generate a protected copolymer (Intermediate-1); treating the protected copolymer to partially depolymerize the protected copolymer and deprotect benzyl protected groups thereby generating a partially depolymerized, benzyl-deprotected product (Intermediate-2); and treating the partially depolymerized product to deprotect TFA-protected lysines thereby generating a TFA-deprotected product (Intermediate-3); and further processing the Intermediate-3 to create glatiramer acetate, wherein the improvement comprises: adjusting the water present during at least a portion of the depolymerization step so that amount water is present during at least
  • a method for preparing a composition comprising glatiramer acetate comprising: polymerizing N-carboxy anhydrides of L-alanine, benzyl- protected L-glutamic acid, trifluoroacetic acid (TFA) protected L-lysine and L-tyrosine to generate a protected copolymer (Intermediate-1); treating the protected copolymer to partially depolymerize the protected copolymer and deprotect benzyl protected groups thereby generating a partially depolymerized, benzyl-deprotected product (Intermediate-2); treating the partially depolymerized, benzyl-deprotected product to deprotect TFA-protected lysines thereby generating acetate TFA-deprotected product (Intermediate-3); and further processing Intermediate-3 to create glatiramer acetate, wherein the improvement comprises: controlling the water present during at least a portion of the depolymerization step so that
  • water is present, adjusted or controlled at the beginning of the depolymerization step; water is added during the depolymerization step; the water present during the depolymerization step is present within a predetermined range (e.g., the predetermined range is 4 - 25%, 5 - 25%, 4-20%, 4-16%, 7- 15%, 8-14%, 9-13%, 10-12%,_13 - 19%, 14 - 18% w/w against Intermediate-1); the depolymerization proceeds for 16-64 hrs, preferably at least 25 hrs (e.g., 25-55 hrs, at least 30 hrs, 30-50 hrs, at least 40 hrs, 43-47 hrs); the depolymerization reaction is carried out at 17-35° C, e.g., 18-30° C, 18-22° C; the depolymerization step comprises contacting the protected copolymer with a solution comprising phenol, HBr and acetic acid; the concentration of
  • a method for preparing a composition comprising glatiramer acetate comprising: polymerizing N-carboxy anhydrides of L-alanine, benzyl-protected L- glutamic acid, trifluoroacetic acid (TFA) protected L-lysine and L-tyrosine to generate a protected copolymer; treating the protected copolymer to partially depolymerize the protected copolymer and deprotect benzyl protected groups thereby generating a partially depolymerized product; treating the partially depolymerized product to deprotect TFA-protected lysines thereby generating a TFA-deprotected product; and processing the TFA-deprotected product to create glatiramer acetate, wherein water is present during at least a portion of the depolymerization step.
  • TFA trifluoroacetic acid
  • An additional method is a method for preparing a composition comprising glatiramer acetate, comprising: polymerizing N-carboxy anhydrides of L-alanine, benzyl- protected L-glutamic acid, trifluoroacetic acid (TFA) protected L-lysine and L-tyrosine to generate a protected copolymer; treating the protected copolymer to partially depolymerize the protected copolymer and deprotect benzyl protected groups thereby generating a partially depolymerized product; treating the partially depolymerized product to deprotect TFA- protected lysines thereby generating glatiramer acetate; and purifying the glatiramer acetate to create purified glatiramer acetate, wherein water is present during at least a portion of the depolymerization step within a predetermined range.
  • TFA trifluoroacetic acid
  • An additional described method is a method for preparing a composition comprising glatiramer acetate, comprising: polymerizing N-carboxy anhydrides of L-alanine, benzyl- protected L-glutamic acid, trifluoroacetic acid (TFA) protected L-lysine and L-tyrosine to generate a protected copolymer; treating the protected copolymer to partially depolymerize the protected copolymer and deprotect benzyl protected groups thereby generating a partially depolymerized product; treating the partially depolymerized product to deprotect TFA- protected lysines thereby generating a TFA-deprotected product;; and processing the a TFA- deprotected product; to create glatiramer acetate, wherein the water present during at least a portion of the depolymerization step is controlled to be within a predetermined range.
  • TFA trifluoroacetic acid
  • water is present, adjusted or controlled at the beginning of the depolymerization step; water is added during the depolymerization step; the water present during the depolymerization step is present within a predetermined range (e.g., the predetermined range is 4 - 25%, 5 - 25%, 13 - 19%, 14 - 18% w/w against Intermediate- 1); the depolymerization proceeds for at least 25 hrs (e.g., at least 30 hrs or at least 40 hrs); the depolymerization step comprises contacting the protected copolymer with a solution comprising phenol, HBr and acetic acid; the concentration of pyroglu in the purified glatiramer acetate is 2000-7000 ppm (e.g., 2500-6000 ppm; 2500-5500 ppm; 3000-5000 ppm; 3500-4500 ppm, 2400-6500 ppm (0.24%-0.65% w/w); the Mp
  • a "copolymer”, “amino acid copolymer” or “amino acid copolymer preparation” is a heterogeneous mixture of polypeptides comprising a defined plurality of different amino acids (typically between 2-10, e.g., between 3-6, different amino acids).
  • a copolymer may be prepared from the polymerization of individual amino acids.
  • the term "amino acid” is not limited to naturally occurring amino acids, but can include amino acid derivatives and/or amino acid analogs.
  • one or more of the amino acids can be a homotyrosine.
  • an amino acid copolymer having one or more non-peptide or peptidomimetic bonds between two adjacent residues is included within this definition.
  • Figure 1 depicts the structure of pyro-Glu.
  • Figure 2 is a graph depicting the results of studies on the effect of the presence water in the depolymerization reaction used in glatiramer acetate production.
  • the production of GA entails polymerization of amino acids to produce a mixture of peptides, referred to as Intermediate- 1 , followed by partial depolymerization and deprotection of Intermediate- 1 to yield Intermediate-2. It has now been found that the level of pyro-Glu in GA can be effectively controlled by controlling the water present during the depolymerization step of the GA manufacturing process, for example, by adjusting the water content at the beginning of and/or during the depolymerization step, e.g., by adding water to a predetermined level at the beginning or during the depolymerization step.
  • the pyro-Glu content of copolymer or GA be 2000 to 7000 ppm, e.g., 2500-5500 ppm, e.g., 3000-5000 ppm, e.g., 3500-4500 ppm, 2400-6500 ppm, and the water present during the depolymerization reaction or added at the end of the depolymerization reaction is preferably controlled or adjusted to achieve this specified pyro-Glu content.
  • the peak molecular weight (Mp) of GA be 5,000 to 9,000 Da, e.g., 6,000 to 8,000 Da, as measured as described in U.S. Pat. 7,074,580.
  • the process for the manufacture of glatiramer acetate includes the following steps:
  • Step 1 polymerization of N-carboxy anhydrides of L-alanine, benzyl-protected L-glutamic acid, trifluoroacetic acid (TFA) protected L-lysine and L-tyrosine (collectively referred to as NCAs) to result in a protected copolymer
  • Step 2 depolymerization and benzyl deprotection of Intermediate- 1 using hydrobromic acid in acetic acid (e.g., phenol treated 33% HBr/acetic acid), and
  • Step 3 deprotection of the TFA-protected lysines on Intermediate-2 (e.g., by treatment with piperdine) to create Intermediate-3, followed by processing to generate GA and further purification and drying of the isolated GA drug substance.
  • Step 1 of GA manufacture the NCAs are co-polymerized in a predetermined ratio using diethylamine as an initiator. Upon consumption of the NCA components, the reaction mixture is quenched in water. The resulting protected polymer (Intermediate- 1) is isolated and dried.
  • Step 2 of GA manufacture Intermediate- 1 is treated with phenol-treated 33% HBr in acetic acid (HBr/AcOH). This results in the cleavage of the benzyl protecting group on the glutamic acids as well as cleavage of peptide bonds throughout the polymer. After a period of time the reaction is quenched with water, and the product polymer is isolated by filtration and washed with water.
  • the product polymer, Intermediate-2 has a reduced molecular weight relative to Intermediate- 1.
  • Intermediate-2 is dried before proceeding to Step 3.
  • Intermediate-2 is treated with aqueous piperidine to remove the trifluoroacetyl group on the lysines.
  • the resulting copolymer, Intermediate-3 is subsequently purified using diafiltration/ultrafiltration and the resulting acetate salt is dried to produce Glatiramer Acetate drug substance.
  • GA with a pyro-Glu content of about 4,000 ppm and a peak molecular weight (Mp) about 7,000 Da can prepared by having water present in the depolymerization reaction at about 16% w/w against Intermediate- 1.
  • the amount of water present is expressed here relative to the amount Intermediate 1, the amount of water present can be expressed in any convenient manner, for example: w/w against the weight of Intermediate- 1 added to the depolymerization reaction; w/w against the weight of phenol used to treat the HBr/acetic acid added to depolymerization reaction; w/w against the total weight of HBr/acetic acid added to depolymerization reaction; v/v against the total volume of HBr/acetic acid added to the depolymerization reaction; or w/w against the total weight of the depolymerization reaction.
  • the amount of water present relative to HBr/AcOH on a v/v basis can be calculated from the amount of water present relative to Intermediate- 1 on a w/w basis as follows:
  • the water present during the depolymerization reaction can include water present in the Intermediate-1 added to the depolymerization reaction (e.g., by using Intermediate-1 that is not fully dried) and/or water that is added at the beginning or during the depolymerization reaction.
  • the amount of water present during at least a portion of the depolymerization reaction can be controlled by adding water to the reaction to achieve a predetermined level of water or by having a certain amount of water present in the Intermediate- 1 added to the reaction or by a combination of adding water and having water present in the Intermediate- 1.
  • the amount of water present can be controlled by simply having a reasonably consistent amount of water present in the Intermediate- 1.
  • Water can be added to the depolymerization reaction at any time, but is most often present at a predetermined level, e.g., 4 - 25%, 5-25%, 10-20%, 4- 20%, 4-16%, 7-15%, 8-14%, 9-13%, 10-12%, 13-19%, 14-18%, 15-17%, or 16% w/w against the weight of Intermediate- 1, at the beginning of the depolymerization reaction. Because the depolymerization reaction can both consume and produce water, the amount of water present can change slightly over the course of the depolymerization reaction.
  • the amount of water present during the depolymerization step can impact the pyro- GIu content and molecular weight of the resulting GA, as shown by the experiments described below. However, the amount of water present during the depolymerization step can vary over a reasonable range and still be compatible with the production of GA having a desirable pyro-Glu content and molecular weight.
  • the molecular weight (Mp) scale (Da) is on the left axis
  • the pyro-Glu concentration scale (ppm) is on the right axis.
  • the time of Depolymerization reaction A no added water
  • the time of Depolymerization reaction B water present at 16% w/w against intermediate- 1 is on the lower horizontal axis.
  • the scale of the graph is such that the horizontal line labeled "Midpoint of desired range of GPC-Mp (Da)/Midpoint of the desired range of pyroGlu (ppm)" indicates both one desirable Mp molecular weight (7,000 Da) and one desirable pyro-Glu concentration for GA (4,000 ppm).
  • the lines labeled MW A and MW B depict the Mp molecular weight of the GA produced from material removed from Depolymerization reaction A and Depolymerization reaction B, respectively, at various time points.
  • the lines labeled Py A and Pye depict the concentration pyro-Glu in the GA produced from material removed from Depolymerization reaction A and Depolymerization reaction B, respectively, at various time points.
  • pyro-Glu concentration of GA was measured as follows. N-terminal pyro-Glu residues were cleaved using Pyrococcus furiosus pyro-glutamate aminopeptidase. Pyro-Glu in the resulting enzymatic hydrolysate is isolated by reverse phase liquid chromatography followed by detection at 200 nm using a reference standard curve prepared with known concentrations of L-Pyro-glutamate. Neurotensin (a commercially available polypeptide having 100% pyro-glutamate at the N-terminus) is assayed as a control to ensure the acceptability of the digestion and adequacy of the HPLC separation.
  • the chromatographic analysis is performed using a Waters Atlantis Cl 8 HPLC column and an isocratic mobile phase consisting of 100% Water, adjusted to pH 2.1 with phosphoric acid. Samples and Standards are held at 2-8 0 C. The peak corresponding to the pyro-glutamate moiety elutes at a retention time of approximately 12 minutes. The direct measure of pyro- glutamate content is on a w/w basis and the results are expressed as ppm (microgram/gram).

Abstract

Methods of making copolymers are described.

Description

CONTROL OF COPOLYMER COMPOSITIONS
BACKGROUND
[0001] Glatiramer acetate (also known as copolymer- 1 and marketed as the active ingredient in COPAXONE® by Teva Pharmaceutical Industries Ltd., Israel) is used in the treatment of the relapsing-remitting form of multiple sclerosis (RRMS). According to the COPAXONE® product label, glatiramer acetate (GA) consists of the acetate salts of synthetic polypeptides containing four naturally occurring amino acids: L- glutamic acid, L-alanine, L- tyrosine, and L-lysine with a reported average molar fraction of 0.141, 0.427, 0.095, and 0.338, respectively. Chemically, glatiramer acetate is designated L-glutamic acid polymer with L- alanine, L-lysine and L- tyrosine, acetate (salt). Its structural formula is:
(GIu 1 Ala , Lys . Tyr)x« XCH3COO H
(C5H9NO4* C3H7N O2* C6Hi 4N2O2* C9H1 ^ NO3)x #xC2H4O2 CAS - 147245-92-9
SUMMARY OF THE INVENTION
[0002] The invention is based, at least in part, on the identification of methods for controlling the level of L-pyroGlutamic Acid (pyro-Glu) in glatiramer acetate (GA). Pyro-Glu is present in GA, and the ability to control the level of pyro-Glu in GA is useful in controlling both product and process quality in the manufacture of GA.
[0003] Described herein is a method for preparing a composition comprising glatiramer acetate, comprising: polymerizing N-carboxy anhydrides of L-alanine, benzyl-protected L- glutamic acid, trifluoroacetic acid (TFA) protected L-lysine and L-tyrosine to generate a protected copolymer (Intermediate- 1); treating the protected copolymer to partially depolymerize the protected copolymer and deprotect benzyl protected groups thereby generating a partially depolymerized, benzyl -deprotect ed product (Intermediate-2); treating the partially depolymerized product to deprotect TFA-protected lysines thereby generating a TFA- deprotected product (Intermediate-3) and further processing the Intermediate-3 to create glatiramer acetate, wherein the improvement comprises: having water present during at least a portion of the depolymerization step.
[0004] Also described herein is a method for preparing a composition comprising glatiramer acetate, comprising: polymerizing N-carboxy anhydrides of L-alanine, benzyl- protected L-glutamic acid, trifluoroacetic acid (TFA) protected L-lysine and L-tyrosine to generate a protected copolymer (Intermediate-1); treating the protected copolymer to partially depolymerize the protected copolymer and deprotect benzyl protected groups thereby generating a partially depolymerized, benzyl-deprotected product (Intermediate-2); and treating the partially depolymerized product to deprotect TFA-protected lysines thereby generating a TFA-deprotected product (Intermediate-3); and further processing the Intermediate-3 to create glatiramer acetate, wherein the improvement comprises: adjusting the water present during at least a portion of the depolymerization step so that amount water is present during at least a portion of the depolymerization step is within a predetermined range.
[0005] Also described herein is a method for preparing a composition comprising glatiramer acetate, comprising: polymerizing N-carboxy anhydrides of L-alanine, benzyl- protected L-glutamic acid, trifluoroacetic acid (TFA) protected L-lysine and L-tyrosine to generate a protected copolymer (Intermediate-1); treating the protected copolymer to partially depolymerize the protected copolymer and deprotect benzyl protected groups thereby generating a partially depolymerized, benzyl-deprotected product (Intermediate-2); treating the partially depolymerized, benzyl-deprotected product to deprotect TFA-protected lysines thereby generating acetate TFA-deprotected product (Intermediate-3); and further processing Intermediate-3 to create glatiramer acetate, wherein the improvement comprises: controlling the water present during at least a portion of the depolymerization step so that amount water is present during at least a portion of the depolymerization step is within a predetermined range.
[0006] In various embodiments of the forgoing methods: water is present, adjusted or controlled at the beginning of the depolymerization step; water is added during the depolymerization step; the water present during the depolymerization step is present within a predetermined range (e.g., the predetermined range is 4 - 25%, 5 - 25%, 4-20%, 4-16%, 7- 15%, 8-14%, 9-13%, 10-12%,_13 - 19%, 14 - 18% w/w against Intermediate-1); the depolymerization proceeds for 16-64 hrs, preferably at least 25 hrs (e.g., 25-55 hrs, at least 30 hrs, 30-50 hrs, at least 40 hrs, 43-47 hrs); the depolymerization reaction is carried out at 17-35° C, e.g., 18-30° C, 18-22° C; the depolymerization step comprises contacting the protected copolymer with a solution comprising phenol, HBr and acetic acid; the concentration of pyroglu in the purified glatiramer acetate is 2000-7000 ppm (e.g., 2500-6000 ppm; 2500-5500 ppm; 3000-5000 ppm; 3500-4500 ppm, 2400-6500 ppm); the Mp of the purified glatiramer acetate is 5,000-9,000 Da (e.g., 6,500-7,500 Da); in one embodiment water is present during the depolymerization step at 11.2% w/w against Intermediate- 1 , the depolymerization proceeds for 43-47 hrs at 18-22° C and the process produces purified glatiramer acetate in which pyro- GIu is present at 0.24-0.65 % w/w (2400-6500 ppm). The improvement further comprises: preparing a pharmaceutical composition comprising at least a portion of the purified glatiramer acetate; and in some cases the method further includes measuring the amount of water in the depolymerization step at least once.
[0007] Also described is a method for preparing a composition comprising glatiramer acetate, comprising: polymerizing N-carboxy anhydrides of L-alanine, benzyl-protected L- glutamic acid, trifluoroacetic acid (TFA) protected L-lysine and L-tyrosine to generate a protected copolymer; treating the protected copolymer to partially depolymerize the protected copolymer and deprotect benzyl protected groups thereby generating a partially depolymerized product; treating the partially depolymerized product to deprotect TFA-protected lysines thereby generating a TFA-deprotected product; and processing the TFA-deprotected product to create glatiramer acetate, wherein water is present during at least a portion of the depolymerization step.
[0008] An additional method is a method for preparing a composition comprising glatiramer acetate, comprising: polymerizing N-carboxy anhydrides of L-alanine, benzyl- protected L-glutamic acid, trifluoroacetic acid (TFA) protected L-lysine and L-tyrosine to generate a protected copolymer; treating the protected copolymer to partially depolymerize the protected copolymer and deprotect benzyl protected groups thereby generating a partially depolymerized product; treating the partially depolymerized product to deprotect TFA- protected lysines thereby generating glatiramer acetate; and purifying the glatiramer acetate to create purified glatiramer acetate, wherein water is present during at least a portion of the depolymerization step within a predetermined range.
[0009] An additional described method is a method for preparing a composition comprising glatiramer acetate, comprising: polymerizing N-carboxy anhydrides of L-alanine, benzyl- protected L-glutamic acid, trifluoroacetic acid (TFA) protected L-lysine and L-tyrosine to generate a protected copolymer; treating the protected copolymer to partially depolymerize the protected copolymer and deprotect benzyl protected groups thereby generating a partially depolymerized product; treating the partially depolymerized product to deprotect TFA- protected lysines thereby generating a TFA-deprotected product;; and processing the a TFA- deprotected product; to create glatiramer acetate, wherein the water present during at least a portion of the depolymerization step is controlled to be within a predetermined range.
[0010] In various embodiments of the foregoing methods: water is present, adjusted or controlled at the beginning of the depolymerization step; water is added during the depolymerization step; the water present during the depolymerization step is present within a predetermined range (e.g., the predetermined range is 4 - 25%, 5 - 25%, 13 - 19%, 14 - 18% w/w against Intermediate- 1); the depolymerization proceeds for at least 25 hrs (e.g., at least 30 hrs or at least 40 hrs); the depolymerization step comprises contacting the protected copolymer with a solution comprising phenol, HBr and acetic acid; the concentration of pyroglu in the purified glatiramer acetate is 2000-7000 ppm (e.g., 2500-6000 ppm; 2500-5500 ppm; 3000-5000 ppm; 3500-4500 ppm, 2400-6500 ppm (0.24%-0.65% w/w); the the Mp of the purified glatiramer acetate is 5,000-9,000 Da (e.g., 6,500-7,500 Da); the improvement further comprises: preparing a pharmaceutical composition comprising at least a portion of the purified glatiramer acetate; the step of treating the partially depolymerized product to deprotect TFA- protected lysines comprises treating the depolymerized product with piperidine; the protected copolymer is isolated and at least partially dried prior to treating the protected copolymer to partially depolymerize the protected copolymer and deprotect benzyl protected groups; the partially depolymerized product is isolated and at least partially dried prior to the step of treating the partially depolymerized product to deprotect TFA-protected lysines; in some cases the method further includes measuring the amount of water in the depolymerization step at least once. [0011] As used herein, a "copolymer", "amino acid copolymer" or "amino acid copolymer preparation" is a heterogeneous mixture of polypeptides comprising a defined plurality of different amino acids (typically between 2-10, e.g., between 3-6, different amino acids). A copolymer may be prepared from the polymerization of individual amino acids. The term "amino acid" is not limited to naturally occurring amino acids, but can include amino acid derivatives and/or amino acid analogs. For example, in an amino acid copolymer comprising tyrosine amino acids, one or more of the amino acids can be a homotyrosine. Further, an amino acid copolymer having one or more non-peptide or peptidomimetic bonds between two adjacent residues is included within this definition.
BRIEF DESCRIPTION OF THE FIGURES
[0012] Figure 1 depicts the structure of pyro-Glu.
[0013] Figure 2 is a graph depicting the results of studies on the effect of the presence water in the depolymerization reaction used in glatiramer acetate production.
DETAILED DESCRIPTION OF THE INVENTION
[0014] Other than a statement about molecular weight and amino acid composition, which are recited in the FDA-approved label for the product, the label and other available literature for COPAXONE® does not provide detailed information about the physiochemical characteristics of the product. It has been previously found that Pyro-Glu (Figure 1) is a component of Copaxone® (glatiramer acetate or GA) that is present within a predetermined range (US Serial No. 12/408,058). For example, in many cases the pyro-Glu content of a GA preparation can be between 2000 ppm and 7000 ppm or 2400-6500 ppm.
[0015] The production of GA entails polymerization of amino acids to produce a mixture of peptides, referred to as Intermediate- 1 , followed by partial depolymerization and deprotection of Intermediate- 1 to yield Intermediate-2. It has now been found that the level of pyro-Glu in GA can be effectively controlled by controlling the water present during the depolymerization step of the GA manufacturing process, for example, by adjusting the water content at the beginning of and/or during the depolymerization step, e.g., by adding water to a predetermined level at the beginning or during the depolymerization step. Moreover, it has now been found that by properly controlling (e.g., adjusting) the amount of water present during the depolymerization step and the duration of the depolymerization step it is possible to produce GA with a specified pyro-Glu content and a specified peak molecular weight (Mp). In many cases it is specified to have the pyro-Glu content of copolymer or GA be 2000 to 7000 ppm, e.g., 2500-5500 ppm, e.g., 3000-5000 ppm, e.g., 3500-4500 ppm, 2400-6500 ppm, and the water present during the depolymerization reaction or added at the end of the depolymerization reaction is preferably controlled or adjusted to achieve this specified pyro-Glu content. In many cases it is desirable to have the peak molecular weight (Mp) of GA be 5,000 to 9,000 Da, e.g., 6,000 to 8,000 Da, as measured as described in U.S. Pat. 7,074,580.
Manufacture of Glatiramer Acetate
[0016] Generally, the process for the manufacture of glatiramer acetate includes the following steps:
Step 1 : polymerization of N-carboxy anhydrides of L-alanine, benzyl-protected L-glutamic acid, trifluoroacetic acid (TFA) protected L-lysine and L-tyrosine (collectively referred to as NCAs) to result in a protected copolymer
(Intermediate- 1),
Step 2: depolymerization and benzyl deprotection of Intermediate- 1 using hydrobromic acid in acetic acid (e.g., phenol treated 33% HBr/acetic acid), and
Step 3: deprotection of the TFA-protected lysines on Intermediate-2 (e.g., by treatment with piperdine) to create Intermediate-3, followed by processing to generate GA and further purification and drying of the isolated GA drug substance.
[0017] In Step 1 of GA manufacture, the NCAs are co-polymerized in a predetermined ratio using diethylamine as an initiator. Upon consumption of the NCA components, the reaction mixture is quenched in water. The resulting protected polymer (Intermediate- 1) is isolated and dried. In Step 2 of GA manufacture, Intermediate- 1 is treated with phenol-treated 33% HBr in acetic acid (HBr/AcOH). This results in the cleavage of the benzyl protecting group on the glutamic acids as well as cleavage of peptide bonds throughout the polymer. After a period of time the reaction is quenched with water, and the product polymer is isolated by filtration and washed with water. The product polymer, Intermediate-2, has a reduced molecular weight relative to Intermediate- 1. Intermediate-2 is dried before proceeding to Step 3. hi Step 3, Intermediate-2 is treated with aqueous piperidine to remove the trifluoroacetyl group on the lysines. The resulting copolymer, Intermediate-3, is subsequently purified using diafiltration/ultrafiltration and the resulting acetate salt is dried to produce Glatiramer Acetate drug substance.
[0018] Methods for the manufacture of GA are described in the following publications: U.S. Patent No. 3,849,550; WO 95/031990 and US 2007-0021324.
Control of pyro-Glu and Depolvmerization with Water
[0019J As shown below, GA with a pyro-Glu content of about 4,000 ppm and a peak molecular weight (Mp) about 7,000 Da can prepared by having water present in the depolymerization reaction at about 16% w/w against Intermediate- 1. While the amount of water present is expressed here relative to the amount Intermediate 1, the amount of water present can be expressed in any convenient manner, for example: w/w against the weight of Intermediate- 1 added to the depolymerization reaction; w/w against the weight of phenol used to treat the HBr/acetic acid added to depolymerization reaction; w/w against the total weight of HBr/acetic acid added to depolymerization reaction; v/v against the total volume of HBr/acetic acid added to the depolymerization reaction; or w/w against the total weight of the depolymerization reaction. Thus, the amount of water present relative to HBr/AcOH on a v/v basis can be calculated from the amount of water present relative to Intermediate- 1 on a w/w basis as follows:
Vθl(water) A/θl(HBR/AcθH) = (Wt<water) / Wt ( Intermediate- 1 )) X (Wt ( Intermediate- 1 ) / Wt (HBr/AcOH)) X (Wt (HBr/ AcOH ) / Vol (HBr/AcOH)) X (Vol (water ) / Wt (water) ) = (Wt(water) / Wt (Intermediate- 1)) X (Wt (Intermediate-1 ) / Wt (HBr/AcOH)) X (Density (HBr/AcOH ) / Density (water))
[0020] The water present during the depolymerization reaction can include water present in the Intermediate-1 added to the depolymerization reaction (e.g., by using Intermediate-1 that is not fully dried) and/or water that is added at the beginning or during the depolymerization reaction. Thus, the amount of water present during at least a portion of the depolymerization reaction can be controlled by adding water to the reaction to achieve a predetermined level of water or by having a certain amount of water present in the Intermediate- 1 added to the reaction or by a combination of adding water and having water present in the Intermediate- 1. Thus, the amount of water present can be controlled by simply having a reasonably consistent amount of water present in the Intermediate- 1. Water can be added to the depolymerization reaction at any time, but is most often present at a predetermined level, e.g., 4 - 25%, 5-25%, 10-20%, 4- 20%, 4-16%, 7-15%, 8-14%, 9-13%, 10-12%, 13-19%, 14-18%, 15-17%, or 16% w/w against the weight of Intermediate- 1, at the beginning of the depolymerization reaction. Because the depolymerization reaction can both consume and produce water, the amount of water present can change slightly over the course of the depolymerization reaction.
[0021] The amount of water present during the depolymerization step can impact the pyro- GIu content and molecular weight of the resulting GA, as shown by the experiments described below. However, the amount of water present during the depolymerization step can vary over a reasonable range and still be compatible with the production of GA having a desirable pyro-Glu content and molecular weight.
Examples
Example 1
[0022] The effect of water present during the depolymerization step, Step 2, on the pyro- Glu content and molecular weight of the resulting GA was examined as follows. Intermediate- 1 was produced as described above and divided between two depolymerization reactions (A and B). For Depolymerization reaction A, no water was added. For Depolymerization reaction B, water was added to 16% measured w/w against Intermediate- 1. Depolymerization was allowed to proceed at 20° C. Aliquots removed periodically from each reaction were quenched with water and further processed to produce GA. The pyro-Glu content (ppm), measured as described below, and peak molecular weight (Mp) of each of the resulting GA samples were measured. The results of this analysis are shown in Figure 2. The molecular weight (Mp) scale (Da) is on the left axis, the pyro-Glu concentration scale (ppm) is on the right axis. The time of Depolymerization reaction A (no added water) is on the upper horizontal axis, and the time of Depolymerization reaction B (water present at 16% w/w against intermediate- 1) is on the lower horizontal axis. The scale of the graph is such that the horizontal line labeled "Midpoint of desired range of GPC-Mp (Da)/Midpoint of the desired range of pyroGlu (ppm)" indicates both one desirable Mp molecular weight (7,000 Da) and one desirable pyro-Glu concentration for GA (4,000 ppm). The lines labeled MWA and MWB depict the Mp molecular weight of the GA produced from material removed from Depolymerization reaction A and Depolymerization reaction B, respectively, at various time points. The lines labeled PyA and Pye depict the concentration pyro-Glu in the GA produced from material removed from Depolymerization reaction A and Depolymerization reaction B, respectively, at various time points.
[0023] In the absence of added water, the desired combination of molecular weight and pyro-Glu concentration is not achieved. As can be seen in Figure 2, after about 12 hours (scale on upper horizontal axis) Depolymerization reaction A (no added water) produces material that yields GA having a desired pyro-Glu concentration (about 4,000 ppm), but the molecular weight (Mp) of the GA is about 7,400 Da, above the desired 7,000 Da. As can be also seen in Figure 2, after about 26 hours (scale on upper horizontal axis) Depolymerization reaction A (no added water) produces material that yields GA having a desired Mp (about 7,000 Da), but the pyro-Glu concentration of the GA is greater than 6,000 ppm, which is above 4,000 ppm (the midpoint of the desired range). In contrast, when water is added to the depolymerization reaction to 16% (w/w against Intermediate- 1), the desired combination of molecular weight and pyro-Glu concentration is achieved. As can also be seen from Figure 2, after about 43 hours Depolymerization reaction B (16% water w/w against Intermediate- 1) produces material that yields GA having a desired molecular weight (Mp about 7,000 Da) and a desired pyro-Glu concentration (about 4,000 ppm).
Example 2
[0024] In the study described above pyro-Glu concentration of GA was measured as follows. N-terminal pyro-Glu residues were cleaved using Pyrococcus furiosus pyro-glutamate aminopeptidase. Pyro-Glu in the resulting enzymatic hydrolysate is isolated by reverse phase liquid chromatography followed by detection at 200 nm using a reference standard curve prepared with known concentrations of L-Pyro-glutamate. Neurotensin (a commercially available polypeptide having 100% pyro-glutamate at the N-terminus) is assayed as a control to ensure the acceptability of the digestion and adequacy of the HPLC separation. The chromatographic analysis is performed using a Waters Atlantis Cl 8 HPLC column and an isocratic mobile phase consisting of 100% Water, adjusted to pH 2.1 with phosphoric acid. Samples and Standards are held at 2-80C. The peak corresponding to the pyro-glutamate moiety elutes at a retention time of approximately 12 minutes. The direct measure of pyro- glutamate content is on a w/w basis and the results are expressed as ppm (microgram/gram).

Claims

1. A method for preparing a composition comprising glatiramer acetate, comprising: polymerizing N-carboxy anhydrides of L-alanine, benzyl-protected L-glutamic acid, trifluoroacetic acid (TFA) protected L-lysine and L-tyrosine to generate a protected copolymer; treating the protected copolymer to partially depolymerize the protected copolymer and deprotect benzyl protected groups thereby generating a partially depolymerized product; treating the partially depolymerized product to deprotect TFA-protected lysines and generate glatiramer acetate; and purifying the glatiramer acetate to create purified glatiramer acetate, wherein the improvement comprises: having water present during at least a portion of the depolymerization step.
2. A method for preparing a composition comprising glatiramer acetate, comprising: polymerizing N-carboxy anhydrides of L-alanine, benzyl-protected L-glutamic acid, trifluoroacetic acid (TFA) protected L-lysine and L-tyrosine to generate a protected copolymer; treating the protected copolymer to partially depolymerize the protected copolymer and deprotect benzyl protected groups thereby generating a partially depolymerized product; and treating the partially depolymerized product to deprotect TFA-protected lysines and generate glatiramer acetate; and purifying the glatiramer acetate to create purified glatiramer acetate, wherein the improvement comprises: adjusting the water present during at least a portion of the depolymerization step so that amount water is present during at least a portion of the depolymerization step is within a predetermined range.
3. A method for preparing a composition comprising glatiramer acetate, comprising: polymerizing N-carboxy anhydrides of L-alanine, benzyl-protected L-glutamic acid, trifluoroacetic acid (TFA) protected L-lysine and L-tyrosine to generate a protected copolymer; treating the protected copolymer to partially depolymerize the protected copolymer and deprotect benzyl protected groups thereby generating a partially depolymerized product; and treating the partially depolymerized product to deprotect TFA-protected lysines and generate glatiramer acetate; and purifying the glatiramer acetate to create purified glatiramer acetate, wherein the improvement comprises: controlling the water present during at least a portion of the depolymerization step so that amount water is present during at least a portion of the depolymerization step is within a predetermined range.
4. The method of any of claims 1-3 wherein water is present, adjusted or controlled at the beginning of the depolymerization step.
5. The method of any of claims 1 -3 wherein water is added during the depolymerization step.
6. The method of claim 1 wherein the water present during the depolymerization step is present within a predetermined range.
7. The method of any of claims 2, 3 and 6 wherein the predetermined range is 4 — 25% w/w against Intermediate- 1
8. The method of any of claims 2, 3 and 6 wherein the predetermined range is 13 —
19% w/w against Intermediate- 1.
9. The method of any of claims 2, 3 and 6 wherein the predetermined range is 14 — 18% w/w against Intermediate- 1.
10. The method of any of claims 1 -9 wherein the depolymerization proceeds for at least 25 hrs.
11. The method of claim 10 wherein the depolymerization proceeds for at least 30 hrs.
12. The method of claim 1 1 wherein the depolymerization proceeds for at least 40 hrs.
13. The method of any of claims 1-3 wherein the depolymerization step comprises contacting the protected copolymer with a solution comprising phenol, HBr and acetic acid.
14. The method of any of claims 1 -3 wherein the concentration of pyroglu in the purified glatiramer acetate is 2000-7000 ppm.
15. The method of claim 14, wherein the concentration of pyro-Glu in the purified glatiramer acetate 2500-5500 ppm.
16. The method of claim 14, wherein the concentration of pyro-Glu in the purified glatiramer acetate 3000-5000 ppm.
17. The method of claim 14, wherein the concentration of pyro-Glu in the purified glatiramer acetate 3500-4500 ppm.
18. The method of any of claims 1-17 wherein the Mp of the purified glatiramer acetate is 5,000-9,000 Da.
19. The method of claim 18 wherein the Mp of the purified glatiramer acetate is 6,500-7,500 Da.
20. The method of any of claims 1-19 wherein the improvement further comprises: preparing a pharmaceutical composition comprising at least a portion of the purified glatiramer acetate.
21. A method for preparing a composition comprising glatiramer acetate, comprising: polymerizing N-carboxy anhydrides of L-alanine, benzyl -protected L- glutamic acid, trifluoroacetic acid (TFA) protected L-lysine and L-tyrosine to generate a protected copolymer; treating the protected copolymer to partially depolymerize the protected copolymer and deprotect benzyl protected groups thereby generating a partially depolymerized product; treating the partially depolymerized product to deprotect TFA-protected lysines thereby generating glatiramer acetate; and purifying the glatiramer acetate to create purified glatiramer acetate, wherein water is present during at least a portion of the depolymerization step.
22. A method for preparing a composition comprising glatiramer acetate, comprising: polymerizing N-carboxy anhydrides of L-alanine, benzyl-protected L-glutamic acid, trifluoroacetic acid (TFA) protected L-lysine and L-tyrosine to generate a protected copolymer; treating the protected copolymer to partially depolymerize the protected copolymer and deprotect benzyl protected groups thereby generating a partially depolymerized product; treating the partially depolymerized product to deprotect TFA-protected lysines thereby generating glatiramer acetate; and purifying the glatiramer acetate to create purified glatiramer acetate, wherein water is present during at least a portion of the depolymerization step within a predetermined range.
23. A method for preparing a composition comprising glatiramer acetate, comprising: polymerizing N-carboxy anhydrides of L-alanine, benzyl-protected L-glutamic acid, trifluoroacetic acid (TFA) protected L-lysine and L-tyrosine to generate a protected copolymer; treating the protected copolymer to partially depolymerize the protected copolymer and deprotect benzyl protected groups thereby generating a partially depolymerized product; treating the partially depolymerized product to deprotect TFA-protected lysines thereby generating glatiramer acetate; and purifying the glatiramer acetate to create purified glatiramer acetate, wherein the water present during at least a portion of the depolymerization step is controlled to be within a predetermined range.
24. The method of any of claims 21-23 wherein water is present at the beginning of the depolymerization step.
25. The method of any of claims 21-23 wherein water is added during the depolymerization step.
26. The method of claim 21 wherein the water present during the depolymerization step is present within a predetermined range.
27. The method of any of claims 22, 23 and 26 wherein the predetermined range is 4
- 25% w/w against Intermediate- 1
28. The method of any of claims 22, 23 and 26 wherein the predetermined range is
13 - 19% w/w against Intermediate-1.
29. The method of any of claims 22, 23 and 26 wherein the predetermined range is
14 - 18% w/w against Intermediate- 1.
30. The method of any of claims 21-29 wherein the depolymerization proceeds for at least 25 hrs.
31. The method of claim 30 wherein the depolymerization proceeds for at least 30 hrs.
32. The method of claim 31 wherein the depolymerization proceeds for at least 40 hrs.
33. The method of any of claims 21-23 wherein the depolymerization step comprises contacting the protected copolymer with a solution comprising phenol, HBr and acetic acid.
34. The method of any of claims 21-23 wherein the concentration of pyroglu in the purified glatiramer acetate is 2000-7000 ppm.
35. The method of claim 34, wherein the concentration of pyro-Glu in the purified glatiramer acetate 2500-5500 ppm.
36. The method of claim 34 wherein the concentration of pyro-Glu in the purified glatiramer acetate 3000-5000 ppm.
37. The method of claim 34, wherein the concentration of pyro-Glu in the purified glatiramer acetate 3500-4500 ppm.
38. The method of any of claims 21-37 wherein the Mp of the purified glatiramer acetate is 5,000-9,000 Da.
39. The method of claim 38 wherein the Mp of the purified glatiramer acetate is 6,500-7,500 Da.
40. The method of any of claims 21-39 wherein the protected copolymer is isolated and at least partially dried prior to treating the protected copolymer to partially depolymerize the protected copolymer and deprotect benzyl protected groups.
41. The method of any of claims 21-39 wherein the partially depolymerized product is isolated and at least partially dried prior to the step of treating the partially depolymerized product to deprotect TFA-protected lysines.
42. The method of any of claims 21-39 wherein the step of treating the partially depolymerized product to deprotect TFA-protected lysines comprises treating the depolymerized product with piperidine.
43. The method of any of claims 21-39, further comprising measuring the amount of water in the depolymerization step at least once.
44. The method of any of claims 21-39 further comprising: preparing a pharmaceutical composition comprising at least a portion of the purified glatiramer acetate.
PCT/US2010/029896 2009-04-03 2010-04-05 Control of copolymer compositions WO2010115175A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
ES10715379T ES2523732T5 (en) 2009-04-03 2010-04-05 Control of copolymer compositions
RU2011144566/05A RU2011144566A (en) 2009-04-03 2010-04-05 CONTROL OF COPOLYMER COMPOSITIONS
EP10715379.3A EP2414384B2 (en) 2009-04-03 2010-04-05 Control of copolymer compositions
IL215072A IL215072A0 (en) 2009-04-03 2011-09-11 Control of copolymer compositions

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16660809P 2009-04-03 2009-04-03
US61/166,608 2009-04-03
US24732109P 2009-09-30 2009-09-30
US61/247,321 2009-09-30

Publications (1)

Publication Number Publication Date
WO2010115175A1 true WO2010115175A1 (en) 2010-10-07

Family

ID=42230467

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/029896 WO2010115175A1 (en) 2009-04-03 2010-04-05 Control of copolymer compositions

Country Status (6)

Country Link
US (6) US8859489B2 (en)
EP (1) EP2414384B2 (en)
ES (1) ES2523732T5 (en)
IL (1) IL215072A0 (en)
RU (1) RU2011144566A (en)
WO (1) WO2010115175A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399600B2 (en) 2008-08-07 2013-03-19 Sigma-Aldrich Co. Llc Preparation of low molecular weight polylysine and polyornithine in high yield
US8575198B1 (en) 2011-09-07 2013-11-05 Momenta Pharmaceuticals, Inc. In-process control for the manufacture of glatiramer acetate
CN104844697A (en) * 2014-09-26 2015-08-19 深圳翰宇药业股份有限公司 Glatirameracetate preparation method

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2449865T5 (en) 2008-04-16 2022-11-18 Momenta Pharmaceuticals Inc Analysis of compositions of amino acid copolymers
WO2010115175A1 (en) * 2009-04-03 2010-10-07 Momenta Pharmaceticals, Inc. Control of copolymer compositions
WO2013009885A2 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Evaluation of copolymer diethylamide
WO2013009864A1 (en) * 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Structure assessment of heterogeneous polypeptide mixtures
WO2018106931A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2019036363A1 (en) 2017-08-14 2019-02-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with glatiramer or a pharmaceutically acceptable salt thereof
US20190202984A1 (en) * 2018-01-03 2019-07-04 Kinbio Ltd. Process of preparing glatiramer acetate

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006029393A2 (en) 2004-09-09 2006-03-16 Teva Pharmaceutical Industries, Ltd. Process for preparation of mixtures of polypeptides using purified hydrobromic acid
WO2007022193A2 (en) 2005-08-15 2007-02-22 Wai Hong Chan Process for the preparation of copolymer-1
WO2009129018A1 (en) 2008-04-16 2009-10-22 Momenta Pharmaceuticals, Inc. Analysis of amino acid copolymer compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US5800808A (en) * 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US5858964A (en) 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
US6800287B2 (en) * 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6291310B1 (en) * 1999-11-24 2001-09-18 Fairfield Semiconductor Corporation Method of increasing trench density for semiconductor
JP4200626B2 (en) * 2000-02-28 2008-12-24 株式会社デンソー Method for manufacturing insulated gate type power device
JP4003605B2 (en) 2002-10-15 2007-11-07 富士電機デバイステクノロジー株式会社 Manufacturing method of semiconductor device
CA2411786C (en) * 2002-11-13 2009-01-27 Brantford Chemicals Inc. A process for the preparation of polypeptides from n-carboxyanhydrides of amino acids
CN101044188B (en) 2004-10-29 2010-08-04 桑多斯股份公司 Processes for preparing glatiramer
CN101111252A (en) * 2005-02-02 2008-01-23 泰华制药工业有限公司 Process for producing polypeptide mixtures using hydrogenolysis
US7399712B1 (en) * 2005-10-31 2008-07-15 Novellus Systems, Inc. Method for etching organic hardmasks
KR100695500B1 (en) 2005-12-28 2007-03-16 주식회사 하이닉스반도체 Method for manufacturing the semiconductor device with top round recess-gate pattern
KR100792365B1 (en) 2006-06-30 2008-01-09 주식회사 하이닉스반도체 Method for fabricating recess gate in semiconductor device
US8993722B2 (en) * 2007-07-31 2015-03-31 Natco Pharma Limited Process for the preparation glatiramer acetate (copolymer-1)
WO2009017775A2 (en) * 2007-08-02 2009-02-05 Scinopharm Taiwan Ltd. Process for the preparation of a polypeptide
KR20090075064A (en) * 2008-01-03 2009-07-08 삼성전자주식회사 Method of fabricating semiconductor device having differential gate dielectric layer and related device
AU2009279636A1 (en) 2008-08-07 2010-02-11 Scinopharm Taiwan, Ltd. Synthesis of glatiramer acetate
WO2010115175A1 (en) * 2009-04-03 2010-10-07 Momenta Pharmaceticals, Inc. Control of copolymer compositions
EP2438080B1 (en) 2009-06-04 2013-12-04 Council of Scientific & Industrial Research An Indian registered body incorporated under the Registration of Societies Act (Act XXI of 1860) Process for the preparation of copolymer-1 (cop-1), composed of l-alanine, l-lysine, l-glutamic acid and l-tyrosine for the treatment of multiple sclerosis
AU2012300765A1 (en) * 2011-09-01 2014-03-13 Novartis Ag Adjuvanted formulations of staphylococcus aureus antigens

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006029393A2 (en) 2004-09-09 2006-03-16 Teva Pharmaceutical Industries, Ltd. Process for preparation of mixtures of polypeptides using purified hydrobromic acid
WO2007022193A2 (en) 2005-08-15 2007-02-22 Wai Hong Chan Process for the preparation of copolymer-1
WO2009129018A1 (en) 2008-04-16 2009-10-22 Momenta Pharmaceuticals, Inc. Analysis of amino acid copolymer compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HOLLADAY J E ET AL: "Catalytic hydrogenation of glutamic acid", APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY - PART A ENZYME ENGINEERING AND BIOTECHNOLOGY 200403 US, vol. 115, no. 1-3, March 2004 (2004-03-01), pages 857 - 869, XP002586796, ISSN: 0273-2289 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399600B2 (en) 2008-08-07 2013-03-19 Sigma-Aldrich Co. Llc Preparation of low molecular weight polylysine and polyornithine in high yield
US8575198B1 (en) 2011-09-07 2013-11-05 Momenta Pharmaceuticals, Inc. In-process control for the manufacture of glatiramer acetate
CN104844697A (en) * 2014-09-26 2015-08-19 深圳翰宇药业股份有限公司 Glatirameracetate preparation method
CN104844697B (en) * 2014-09-26 2018-10-23 深圳翰宇药业股份有限公司 The preparation method of acetic acid copaxone
US10259909B2 (en) 2014-09-26 2019-04-16 Hybio Pharmaceutical Co., Ltd. Method for preparing glatiramer acetate

Also Published As

Publication number Publication date
IL215072A0 (en) 2011-11-30
US20230279050A1 (en) 2023-09-07
EP2414384A1 (en) 2012-02-08
RU2011144566A (en) 2013-05-10
EP2414384B1 (en) 2014-09-10
US20110269690A1 (en) 2011-11-03
ES2523732T5 (en) 2023-10-23
EP2414384B2 (en) 2023-05-03
US8859489B2 (en) 2014-10-14
US20170362273A9 (en) 2017-12-21
US8058235B1 (en) 2011-11-15
US20150105535A1 (en) 2015-04-16
US20180258137A1 (en) 2018-09-13
ES2523732T3 (en) 2014-12-01
US20100256039A1 (en) 2010-10-07
US20200172571A1 (en) 2020-06-04

Similar Documents

Publication Publication Date Title
US20200172571A1 (en) Control of copolymer compositions
AU2006211510B2 (en) Process for producing polypeptide mixtures using hydrogenolysis
US10160992B2 (en) Analysis of amino acid copolymer compositions
US8212002B2 (en) Synthesis of glatiramer acetate
AU2017220387B2 (en) Novel alpha conotoxin peptides
Tsuchiya et al. Protease-catalyzed polymerization of tripeptide esters containing unnatural amino acids: α, α-disubstituted and N-alkylated amino acids
Rapaka et al. Strategies in the racemization-free synthesis of polytripeptide models of collagen

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10715379

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 7589/DELNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2010715379

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2011144566

Country of ref document: RU

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE